6-alkynyl-pyridine derivatives

Patent metadata

Field	Value
Publication number	US-9801871-B2
Application number	US-201615283494-A
Country	US
Kind code	B2
Filing date	Oct 3, 2016
Priority date	Aug 11, 2014
Publication date	Oct 31, 2017
Grant date	Oct 31, 2017

Abstract

6-Alkynyl-pyridine of general formula (I)

their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer.

An exemplary compound is

First claim

The invention claimed is:

1. A method for the treatment of a disease which is cancer, wherein the cancer is selected from carcinomas of the brain or ovary, melanomas, acute myeloid leukaemia (AML), chronic lymphatic leukaemias (CLL) and multiple myeloma (MM), which comprises administering to a host suffering from a cancer a therapeutically effective amount of a compound of formula I

wherein
R 1 is selected from the group consisting of hydrogen, —C 1-3 alkyl and halogen;
R 2 is selected from the group consisting of hydrogen, —C 1-3 alkyl and halogen;
R 3 is selected from the group consisting of phenyl,

R 4 is a 5- or 6-membered heteroaryl substituted with —C 1-3 alkyl or —O—C 1-3 alkyl;
or a pharmaceutically acceptable salt thereof,
or a pharmaceutical composition comprising a compound of formula 1 and a pharmaceutically acceptable carrier.

2. The method of claim 1 , wherein the compound of formula 1 according to claim 1 is:

or a pharmaceutically acceptable salt thereof,
or a pharmaceutical composition thereof.

3. The method of claim 1 , wherein the compound of formula 1 according to claim 1 is:

or a pharmaceutically acceptable salt thereof,
or a pharmaceutical composition thereof.

4. The method of claim 1 , wherein the compound of formula 1 according to claim 1 is:

or a pharmaceutically acceptable salt thereof,
or a pharmaceutical composition thereof.

5. The method of claim 1 , wherein the compound of formula 1 according to claim 1 is:

or a pharmaceutically acceptable salt thereof,
or a pharmaceutical composition thereof.

6. The method of claim 1 , wherein the compound of formula 1 according to claim 1 is:

or a pharmaceutically acceptable salt thereof,
or a pharmaceutical composition thereof.

7. The method of claim 1 , wherein the compound of formula 1 according to claim 1 is:

or a pharmaceutically acceptable salt thereof,
or a pharmaceutical composition thereof.

8. The method of claim 1 , wherein the compound of formula 1 according to claim 1 is:

or a pharmaceutically acceptable salt thereof,
or a pharmaceutical composition thereof.

9. The method of claim 1 , wherein the compound of formula 1 according to claim 1 is:

or a pharmaceutically acceptable salt thereof,
or a pharmaceutical composition thereof.

10. The method of claim 1 , wherein the compound of formula 1 according to claim 1 is:

or a pharmaceutically acceptable salt thereof,
or a pharmaceutical composition thereof.

11. The method of claim 1 , wherein the compound of formula 1 according to claim 1 is:

or a pharmaceutically acceptable salt thereof,
or a pharmaceutical composition thereof.

Assignees

• Boehringer Ingelheim Int

Inventors

• Reiser Ulrich

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61K31/506

  not condensed and containing further heterocyclic rings · CPC title

• C07D471/04 Primary

  Ortho-condensed systems · CPC title

• A61K31/4709 Primary

  Non-condensed quinolines and containing further heterocyclic rings · CPC title